Log in to your Inderes Free account to see all free content on this page.
Create account

Biohit

2.64 EUR

-3.30 %

4,936 following
Corporate customer

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-3.30 %
+10.92 %
-19.02 %
-28.46 %
-14.01 %
+4.76 %
+44.26 %
+15.28 %
-49.23 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
40.14M EUR
Turnover
11.01K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
12.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 12.02.2026

Latest extensive report

Released: 15.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
3.6.
2026

General meeting '26

5.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
And it’s no longer just minor friction in receivables. Since Biohit’s impressive turnaround, they have generated a cumulative net profit of just under €8 million on paper during the 2022-2025 financial years. Cash flow tells a slightly different story. I quickly calculated that the...
2/15/2026, 8:04 PM
by JP199
16
I apologize for the really long message. This is somehow very hard for me to summarize briefly, because otherwise the justifications always remain completely insufficient. I tried hard, but this turned into a long explanation. Or is this starting to resemble the TEM1V pattern (VMBO...
2/15/2026, 6:11 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
16
This seems to be a case of the so-called Urpilainen “first of all, I would like to remind you of the royalty income from China” Hefei has been paying them. The new contract structure clearly no longer includes licensing income from a certain point onwards. There will surely be an...
2/16/2026, 8:07 AM
by Antti Siltanen
15
Nasdaq Company News Vertaisarvioitu tutkimus vahvistaa GastroPanel®-testin arvon... Peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy queues A new peer-reviewed publication in the prestigious Helicobacter journal (2026) confirms the clinical utility...
yesterday
by Ashwanga
12
This really good clarification by @JP199 to my own previous ramblings kept playing on my mind disturbingly. I have hyped up the company’s great openings (UK, India, South Korea, Chile) and their immense potential here. In my opinion, this “ketchup bottle effect” is still real. However...
2/17/2026, 6:19 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
8
Phew, wow, and oh my goodness. Huge and most humble thanks to both @JP199 and @Antti_Siltanen !! I admit I was completely in the dark that the situation regarding those receivables is this bad. This is starting to remind me of the TEM1V case one-to-one (1:1). As I have written, I...
2/16/2026, 3:43 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
8
At least in my opinion, the analysis (including management interviews) has highlighted this very well, which is why these receivables/cash flow have been monitored closely from the start If a risk materializes in this regard, no one can at least blame Inderes for ignoring the risk
2/16/2026, 8:24 AM
by JP199
7
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.